From ChildrensHealthDefense.org…
A few months before the first COVID-19 vaccines received Emergency Use Authorization (EUA) in late 2020, a global vaccine safety expert cautioned the rushed circumstances made it essential to “get [safety monitoring] right” by “intensively” and “robustly” scrutinizing adverse events following the experimental rollout.
As this expert stated, “Deploying any new vaccine based on data from expedited clinical trials into a population without a functioning safety monitoring system in place is reckless and irresponsible given the tools that are available.”
Moreover, she added, any investments needed to beef up safety monitoring would be “inexpensive in comparison” to the massive funding allocated to COVID-19 vaccine development and scale-up.
In theory, the U.S. has had a national vaccine safety monitoring system in place since 1990 — the Vaccine Adverse Event Reporting System (VAERS) — intended to function as an “early warning system.”
